Alternative vascularization mechanisms in cancer

Pathology and therapeutic implications

B. Döme, Mary J C Hendrix, S. Paku, J. Tóvári, J. Tímár

Research output: Contribution to journalArticle

279 Citations (Scopus)

Abstract

Although cancer cells are not generally controlled by normal regulatory mechanisms, tumor growth is highly dependent on the supply of oxygen, nutrients, and host-derived regulators. It is now established that tumor vasculature is not necessarily derived from endothelial cell sprouting; instead, cancer tissue can acquire its vasculature by co-option of pre-existing vessels, intussusceptive microvascular growth, postnatal vasculogenesis, glomeruloid angiogenesis, or vasculogenic mimicry. The best-known molecular pathway driving tumor vascularization is the hypoxia-adaptation mechanism. However, a broad and diverse spectrum of genetic aberrations is associated with the development of the "angiogenic phenotype." Based on this knowledge, novel forms of antivascular modalities have been developed in the past decade. When applying these targeted therapies, the stage of tumor progression, the type of vascularization of the given cancer tissue, and the molecular machinery behind the vascularization process all need to be considered. A further challenge is finding the most appropriate combinations of antivascular therapies and standard radio- and chemotherapies. This review intends to integrate our recent knowledge in this field into a rational strategy that could be the basis for developing effective clinical modalities using antivascular therapy for cancer.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalAmerican Journal of Pathology
Volume170
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Pathology
Neoplasms
Therapeutics
Growth
Radiotherapy
Endothelial Cells
Oxygen
Phenotype
Drug Therapy
Food

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Alternative vascularization mechanisms in cancer : Pathology and therapeutic implications. / Döme, B.; Hendrix, Mary J C; Paku, S.; Tóvári, J.; Tímár, J.

In: American Journal of Pathology, Vol. 170, No. 1, 01.2007, p. 1-15.

Research output: Contribution to journalArticle

@article{d28fc7d0e3e44071b99071b9a2fbe18b,
title = "Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications",
abstract = "Although cancer cells are not generally controlled by normal regulatory mechanisms, tumor growth is highly dependent on the supply of oxygen, nutrients, and host-derived regulators. It is now established that tumor vasculature is not necessarily derived from endothelial cell sprouting; instead, cancer tissue can acquire its vasculature by co-option of pre-existing vessels, intussusceptive microvascular growth, postnatal vasculogenesis, glomeruloid angiogenesis, or vasculogenic mimicry. The best-known molecular pathway driving tumor vascularization is the hypoxia-adaptation mechanism. However, a broad and diverse spectrum of genetic aberrations is associated with the development of the {"}angiogenic phenotype.{"} Based on this knowledge, novel forms of antivascular modalities have been developed in the past decade. When applying these targeted therapies, the stage of tumor progression, the type of vascularization of the given cancer tissue, and the molecular machinery behind the vascularization process all need to be considered. A further challenge is finding the most appropriate combinations of antivascular therapies and standard radio- and chemotherapies. This review intends to integrate our recent knowledge in this field into a rational strategy that could be the basis for developing effective clinical modalities using antivascular therapy for cancer.",
author = "B. D{\"o}me and Hendrix, {Mary J C} and S. Paku and J. T{\'o}v{\'a}ri and J. T{\'i}m{\'a}r",
year = "2007",
month = "1",
doi = "10.2353/ajpath.2007.060302",
language = "English",
volume = "170",
pages = "1--15",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Alternative vascularization mechanisms in cancer

T2 - Pathology and therapeutic implications

AU - Döme, B.

AU - Hendrix, Mary J C

AU - Paku, S.

AU - Tóvári, J.

AU - Tímár, J.

PY - 2007/1

Y1 - 2007/1

N2 - Although cancer cells are not generally controlled by normal regulatory mechanisms, tumor growth is highly dependent on the supply of oxygen, nutrients, and host-derived regulators. It is now established that tumor vasculature is not necessarily derived from endothelial cell sprouting; instead, cancer tissue can acquire its vasculature by co-option of pre-existing vessels, intussusceptive microvascular growth, postnatal vasculogenesis, glomeruloid angiogenesis, or vasculogenic mimicry. The best-known molecular pathway driving tumor vascularization is the hypoxia-adaptation mechanism. However, a broad and diverse spectrum of genetic aberrations is associated with the development of the "angiogenic phenotype." Based on this knowledge, novel forms of antivascular modalities have been developed in the past decade. When applying these targeted therapies, the stage of tumor progression, the type of vascularization of the given cancer tissue, and the molecular machinery behind the vascularization process all need to be considered. A further challenge is finding the most appropriate combinations of antivascular therapies and standard radio- and chemotherapies. This review intends to integrate our recent knowledge in this field into a rational strategy that could be the basis for developing effective clinical modalities using antivascular therapy for cancer.

AB - Although cancer cells are not generally controlled by normal regulatory mechanisms, tumor growth is highly dependent on the supply of oxygen, nutrients, and host-derived regulators. It is now established that tumor vasculature is not necessarily derived from endothelial cell sprouting; instead, cancer tissue can acquire its vasculature by co-option of pre-existing vessels, intussusceptive microvascular growth, postnatal vasculogenesis, glomeruloid angiogenesis, or vasculogenic mimicry. The best-known molecular pathway driving tumor vascularization is the hypoxia-adaptation mechanism. However, a broad and diverse spectrum of genetic aberrations is associated with the development of the "angiogenic phenotype." Based on this knowledge, novel forms of antivascular modalities have been developed in the past decade. When applying these targeted therapies, the stage of tumor progression, the type of vascularization of the given cancer tissue, and the molecular machinery behind the vascularization process all need to be considered. A further challenge is finding the most appropriate combinations of antivascular therapies and standard radio- and chemotherapies. This review intends to integrate our recent knowledge in this field into a rational strategy that could be the basis for developing effective clinical modalities using antivascular therapy for cancer.

UR - http://www.scopus.com/inward/record.url?scp=33847048710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847048710&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2007.060302

DO - 10.2353/ajpath.2007.060302

M3 - Article

VL - 170

SP - 1

EP - 15

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 1

ER -